Suzette Girgis

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 910 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +7

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Ajai Chari, Monique C. Minnema, Jesús G. Berdeja et al. · New England Journal of Medicine · 2022 · 576 citations · Full text

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · The Lancet · 2021 · 292 citations

Hematological Malignancy, Medicine, Malignant Blood Disorder +8

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Philippe Moreau, Ievgenii Karamanesht, Maryna Kyselyova et al. · Clinical Pharmacokinetics · 2012 · 84 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +6